

C All authors analysed the data and wrote the manuscript.

F The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

C None declared.

P Not required.

P Not commissioned; internally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.



T Arnaud L, Lebrun-Vignes B, Salem J-E. *Ann Rheum Dis* 2019;**78**:e68.

Received 26 March 2018

Revised 18 April 2018

Accepted 19 April 2018

Published Online First 3 May 2018



► <http://dx.doi.org/10.1136/annrheumdis-2018-213691>

Ann Rheum Dis 2019;**78**:e68. doi:10.1136/annrheumdis-2018-213470

REFERENCES

- 1 Kostine M, Rouxel L, Barnette T, *et al*. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. *Ann Rheum Dis* 2018;**77**:393–8.
- 2 Weber J, Mandala M, Del Vecchio M, *et al*. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med* 2017;**377**:1824–35.
- 3 Kong YC, Flynn JC. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. *Front Immunol* 2014;**5**:206.
- 4 Moslehi JJ, Salem JE, Sosman JA, *et al*. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet* 2018;**391**:933.
- 5 Lindquist M. VigiBase, the WHO Global ICSR Database system: basic facts. *Drug Inf J* 2008;**42**:409–19.
- 6 Brahmer JR, Lacchetti C, Schneider BJ, *et al*. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2018;**JCO.2017.77.638**.